神经丝蛋白在多中心早期症状起病肌萎缩侧索硬化中的评估
本研究在多中心检测了早期(症状起病≤6个月,n=54)和后期(>6个月,n=135)肌萎缩侧索硬化(ALS)患者脑脊液神经丝轻链(NfL)、磷酸化神经丝重链(pNfH)及血清NfL水平。结果显示这些指标在早期和后期ALS中均升高(p<0.0001),且能高敏感度和特异度区分早期ALS与其他神经系统疾病及运动神经元病模仿者,提示神经丝蛋白检测有助于提高早期ALS诊断准确性。
要点
- 脑脊液NfL、pNfH和血清NfL在早期和后期ALS中均显著升高(p<0.0001)。
- 早期ALS中,脑脊液NfL、血清NfL和脑脊液pNfH鉴别其他神经疾病敏感度94%、88%、98%,特异度86%、92%、91%。
- 早期ALS中,上述指标鉴别MND模仿者敏感度89%、100%、78%,特异度94%、90%、98%。
核心结论
- 神经丝蛋白测定有潜力提高症状起病后早期ALS的诊断准确性,且可在多中心间测量。
研究设计与样本
- 多中心研究,检测ALS患者(起病≤6个月n=54,>6个月n=135)及其他神经系统疾病、MND模仿者、其他MND变异型的脑脊液NfL、pNfH和血清NfL水平,采用ELISA和Simoa平台分析。
主要发现
- 早期和后期症状阶段ALS患者脑脊液NfL、pNfH及血清NfL均升高(p<0.0001)。
- 早期ALS中,脑脊液NfL、血清NfL和脑脊液pNfH鉴别其他神经系统疾病敏感度分别为94%、88%、98%,特异度分别为86%、92%、91%。
- 早期ALS中,上述指标鉴别MND模仿者敏感度分别为89%、100%、78%,特异度分别为94%、90%、98%。
- 早期症状阶段组内,神经丝蛋白浓度在不同临床诊断确定性类别间无差异。
- 基线NfL和pNfH水平在随访进展为明确或很可能ALS的患者中无显著差异。
关键数值与推荐
- 早期ALS鉴别其他神经系统疾病:脑脊液NfL敏感度94%、特异度86%;血清NfL敏感度88%、特异度92%;脑脊液pNfH敏感度98%、特异度91%。
- 早期ALS鉴别MND模仿者:脑脊液NfL敏感度89%、特异度94%;血清NfL敏感度100%、特异度90%;脑脊液pNfH敏感度78%、特异度98%。
临床怎么用
- 对于症状起病6个月内的疑似ALS患者,可检测脑脊液NfL、pNfH和血清NfL以辅助鉴别其他神经系统疾病和MND模仿者。
- 神经丝蛋白水平在多中心间可测量,支持其作为早期ALS诊断的生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine neurofilament (Nf) concentrations according to symptom onset and clinical diagnostic certainty categories of amyotrophic lateral sclerosis (ALS). METHODS: We measured Nf light chain (NfL) and phosphorylated Nf heavy chain (pNfH) CSF and NfL serum levels in patients with ALS with first symptom onset ≤6 months (n = 54) or >6 months (n = 135) from sampling, and patients with other neurologic diseases, differential diagnoses of a motor neuron disease (MND mimics), and other MND variants to determine the diagnostic accuracy in patients with ALS with early symptom onset. Samples were received multicentric and analyzed by ELISA and Simoa platform and related to other clinical measures. RESULTS: NfL and pNfH in CSF and NfL in serum were increased in early and later symptomatic phase ALS (p < 0.0001). CSF and serum NfL and CSF pNfH discriminated patients with ALS with early symptom onset from those with other neurologic diseases and MND mimics with high sensitivity (94%, 88%, 98%, and 89%, 100%, 78%) and specificity (86%, 92%, 91%, and 94%, 90%, 98%) and did not vary between clinical diagnostic categories of ALS in the early symptomatic phase group. Baseline NfL and pNfH levels were not significantly different in patients with ALS with clinical progression to definite or probable ALS at follow-up. CONCLUSION: The measurement of Nf has potential to enhance diagnostic accuracy of ALS in those presenting soon after symptom onset, and is measurable across multiple centers. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that CSF and serum Nf concentrations discriminate ALS with early symptom onset from other neurologic diseases.
引用
- Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2017. PMID: 29212830. doi:10.1212/WNL.0000000000004761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。